Genentech : FDA Advisory Committee Reviews Columvi SBLA For DLBCL Treatment In Non-ASCT Candidates
21/5 05:16
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that a U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics License Application or sBLA for Columvi (glofitamab-gxbm) in combination with gemcitabine...